-16%

est. 2Y upside i

HealthcareSeries D+

Type 2 diabetes reversal and metabolic health platform

Rank

#2757

Sector

HealthTech

Est. Liquidity

~4Y

Data Quality

Data: Medium

Given a stale $2B valuation from 2021, high preference overhang, and likely near-term dilution, the expected 2-year return for common stock is -16.1%.

Last updated: July 19, 2026

Bull (20%)+66%

With an IPO window and category leadership in metabolic disease reversal, Virta sustains a 10x revenue multiple on projected $371M revenue, yielding 65.6% net upside after 20% dilution.

Base (40%)-9%

Multiple compresses to 6x in line with public comps, exit at $2.23B, net of preference and 20% dilution yields -8.7% return.

Bear (40%)-64%

Multiple collapses to 3x due to competition from GLP-1 drugs and margin pressures, exit at $1.11B, common recovery limited, net -64.4%.

Est. time to liquidity~4.0 years
Adjusted for competitive dynamics: -20% (raw: -16%, adjustment: -4%)

Preference Stack Risk

high

Funding Intensity

25125%

Total funding $402M on $2B valuation implies 20% preference overhang, significantly diluting common in downside.

Dilution Risk

high

5+ years since last raise, company likely needs new capital; estimated 20% dilution.

Secondary Liquidity

none

No secondary market activity noted.

Product Development — 5 roles

Finance & Legal — 1 role

People & Places — 1 role

View all 21 open roles at Virta Health →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Virta Health's data — designed to show you've done your homework.

  • 1

    “How does Virta plan to defend against the growing adoption of GLP-1 drugs for diabetes and obesity?”

  • 2

    “What is the scalability of outcomes-based contracts, and how does the unit economics look for obesity vs. diabetes patients?”

  • 3

    “Given the 5+ years since the last funding round, what is the company's timeline for an exit or next raise, and how does it affect employee equity liquidity?”

Community

Valuation Sentiment

Our model estimates -16% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.